Form 4: Inmune Bio Reprices Director's Stock Options to $1.50

Inmune Bio, Inc. has repriced 366,000 stock options for Director Timothy J Schroeder to an exercise price of $1.50 per share, matching the closing stock price on November 18, 2025.

Summary

• Inmune Bio, Inc. (INMB) repriced 366,000 outstanding stock options held by Director Timothy J Schroeder.
• The exercise price for these options was reduced to $1.50 per share.
• This new exercise price matches the closing price of Inmune Bio's common stock on The Nasdaq Capital Market on November 18, 2025, the effective date of the repricing.
• The repricing was approved by the Issuer's stockholders.
• All other terms and conditions, including vesting schedules and term, of the repriced options remain unchanged.
• The repriced options were originally granted under the company's 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans.

Sentiment

Score: 3

Explanation: The repricing of options, while beneficial for the option holder, generally reflects poor past stock performance. It's a necessary step to re-incentivize but highlights underlying challenges. The stockholder approval provides some governance comfort, but the event itself is a reaction to negative stock movement.

Positives

• The repricing makes the options significantly 'in-the-money' or closer to it, providing a renewed incentive for Director Schroeder.
• It aligns the director's incentives with current shareholder value, as the exercise price now matches the market price.
• Stockholder approval for the repricing indicates a level of corporate governance oversight.

Negatives

• The need for a repricing suggests a significant decline in the company's stock price from the original, much higher exercise prices (e.g., $24.82, $17.49, $9.92).
• Repricing can be viewed negatively by some investors as it effectively grants new value to existing options, potentially diluting future shareholder value if the stock recovers.
• It may signal a lack of confidence in the stock's ability to reach previous highs in the near term.

Risks

• The underlying risk is the significant decline in the company's stock price that necessitated the repricing, indicating potential operational or market challenges.
• Future stock performance remains uncertain, and the repriced options may still not become significantly valuable if the stock price does not increase above $1.50.
• Shareholder dissatisfaction with executive compensation practices, particularly repricing, could lead to governance issues.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the continued vesting of the repriced options based on the reporting person's service.

Industry Context

Stock option repricing is a practice sometimes employed by companies, particularly in volatile sectors like biotechnology, to re-incentivize executives and directors when the stock price has significantly underperformed, rendering existing options 'underwater.' While it can help retain talent, it often signals past stock performance challenges compared to industry peers who might maintain or increase their stock value.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders may view the repricing negatively as it signals past stock underperformance and could be perceived as dilutive if the stock recovers, as more options are now likely to be exercised.
• Employees/Management: The repricing provides renewed incentive for Director Schroeder and potentially other option holders, aiding in retention and motivation.

Next Steps

• The repriced options will continue to vest according to their original schedules, contingent on Director Schroeder's continued service with Inmune Bio, Inc.

Key Dates

Recommendation

While the repricing of options for a director can be seen as a necessary step to re-incentivize management following a significant stock price decline, it primarily reflects past underperformance. The action itself doesn't introduce new positive catalysts but rather addresses a symptom of previous challenges. Investors should 'hold' to observe if this renewed incentive translates into improved operational performance and sustained stock price recovery, rather than reacting to a compensation adjustment that primarily benefits the option holder in the context of a lower stock price.

Keywords

Inmune Bio, INMB, Stock Option Repricing, SEC Form 4, Executive Compensation, Director Stock Options, Corporate Governance, Equity Incentive Plans, Timothy Schroeder, Nasdaq